September 8, 2017: ACTTION Submits Letter of Intent to FDA for Accelerometry

ACTTION has been assigned a Drug Development Tool number by FDA and submitted a Letter of Intent to begin development of the "Physical Activity Accelerometry Assessment for Analgesic Clinical Trials" (PAACT) and then apply for its qualification as a Clinical Outcome Assessment. ACTTION looks forward to the FDA's response and to developing an evidence-based and state-of-the-art approach for the assessment of physical activity using accelerometry.